Figure 1.
Figure 1. IVIg requires expression of FcγRIIB but not SHIP1 to ameliorate murine ITP. (A) FcγRIIB KO (▿) or control wild-type (○) mice (C57BL/6) were injected with 2 μg anti-integrin αIIb antibody on days 0, 1, 2, and 3. The arrow (↑) denotes injection of anti-integrin αIIb antibody. All mice received an injection of 2 g/kg HSA control protein on day 1, followed by 2 g/kg IVIg on day 2 (↓, denotes injection of HSA or IVIg). Mice were bled daily for platelet enumeration. (B) SHIP1 heterozygous KO (⋄) and homozygous KO (▿) mice and littermate control (○) mice were treated as described in panel A. Data are expressed as mean ± SEM; n = 10 mice/data point. *P < .001 versus control.

IVIg requires expression of FcγRIIB but not SHIP1 to ameliorate murine ITP. (A) FcγRIIB KO (▿) or control wild-type (○) mice (C57BL/6) were injected with 2 μg anti-integrin αIIb antibody on days 0, 1, 2, and 3. The arrow (↑) denotes injection of anti-integrin αIIb antibody. All mice received an injection of 2 g/kg HSA control protein on day 1, followed by 2 g/kg IVIg on day 2 (↓, denotes injection of HSA or IVIg). Mice were bled daily for platelet enumeration. (B) SHIP1 heterozygous KO (⋄) and homozygous KO (▿) mice and littermate control (○) mice were treated as described in panel A. Data are expressed as mean ± SEM; n = 10 mice/data point. *P < .001 versus control.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal